AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03722966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine Replacement Therapy (NRT)
Description: Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
Study NCT01386567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsules oral 1x a day~1 year
Study NCT01386567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim (topical testosterone)
Description: topical~1 tube~1x a day~1 year
Study NCT04063644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vis Glyc Neo
Description: 1 drop in each eye, three times a day.
Study NCT04063644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution
Description: 1 drop in each eye, three times a day.
Study NCT00568204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mexyn-A
Description: Atomised topical self-chilled pressurised spray
Study NCT04466787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spectral Photon Counting Computed Tomography (SPCCT)
Description: The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm.
Study NCT04466787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dual Energy CT (DECT)
Description: The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips
Study NCT03538275 — intervention group
Intervention type: OTHER
Intervention: Monitoring test
Description: Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
Study NCT02540876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilorasertib
Description: Given PO
Study NCT02540876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00653094 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Halevy kit
Description: the use of Halevy kit in Crohn patients with Fistulas
Study NCT01240304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
Study NCT01240304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
Study NCT03722966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Reminders
Description: Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
Study NCT01240304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticoduodenectomy
Description: Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
Study NCT01620008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Description: At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
Study NCT01704794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid + Paludrine + Jobelyn (2mg)
Description: Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
Study NCT03722966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
Study NCT04661839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-HIGIV
Description: COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
Study NCT04661839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
Study NCT01007812 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel, toric, soft contact lens
Study NCT01007812 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Silicone hydrogel, toric, soft contact lens
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provide menu with visual cue and calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provide menu with visual cue but no calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provide menu with visual cue but no calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provide menu with no visual cue but with calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provide menu with no visual cue but with calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01346449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provide menu with no visual cue and no calorie information
Description: Menu to be provided prior to placing the food order.
Study NCT01599767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Study NCT01599767 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Study NCT02940535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphereline (Triptorelin embonate)
Study NCT02940535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl (Triptorelin)
Study NCT02940535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Study NCT02940535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Study NCT03054623 — intervention group
Intervention type: PROCEDURE
Intervention: DRIL procedure
Description: The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
Study NCT03340675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban
Description: Weight based, once daily oral ifetroban
Study NCT03340675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo
Study NCT02204085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GO-203-2c
Study NCT02204085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GO-203-2c + Decitabine
Study NCT02536118 — intervention group
Intervention type: DEVICE
Intervention: Micra Transcatheter Pacing System
Description: The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
Study NCT01300585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
Study NCT01016808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: Q8003 is a combination of morphine sulfate and oxycodone HCl
Study NCT01016808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: One morphine sulfate 12 mg IR capsule q6h
Study NCT01016808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl
Description: One oxycodone HCl 8 mg IR Capsule q6h
Study NCT02337296 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ADHERE
Description: ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence.
Study NCT02337296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHERE
Description: ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence.
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Blood biomarkers
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: GENETIC
Intervention: DNA collection
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary exercise testing
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Exercise stress doppler echocardiography
Description: Observational Study using Imaging and Biomarkers
Study NCT01835054 — intervention group
Intervention type: OTHER
Intervention: Holter ECG
Description: Observational Study using Imaging and Biomarkers
Study NCT01037296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: ablation procedure performed with Hansen robotic navigation system
Study NCT01037296 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter ablation
Description: Ablation will be performed as normal treatment
Study NCT01943110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID adapter (autodisable)
Description: Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
Study NCT01943110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID adapter (side load)
Description: Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03856112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02107365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Description: Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
Study NCT02107365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
Study NCT02107365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
Study NCT02107365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
Study NCT03499210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk ReStore device
Description: The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
Study NCT04007991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
Study NCT04007991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03456583 — intervention group
Intervention type: DEVICE
Intervention: Brevera Breast Biopsy System
Description: The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
Study NCT03634475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP-001
Description: Drug - no placebo
Study NCT00073619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Description: School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
Study NCT00491140 — intervention group
Intervention type: GENETIC
Intervention: Gene mutations analysis and FISH
Description: FISH and mutation analysis of multiple genes
Study NCT04602065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
Description: IBI318, 300mg, Q2W, Intravenous influsion.
Study NCT02669758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Tablets were administered for daily dosing
Study NCT02448264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Study NCT02448264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match BCX7353
Study NCT04779515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
Study NCT04779515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
Study NCT04013230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Visit doctor and nurse at the clinic.
Study NCT04013230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-COP
Description: Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
Study NCT04914858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Its validity and reliability is a reliable scale in Turkey
Study NCT02912650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 250 mg / Acetaminophen 500 mg
Description: 2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
Study NCT02912650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 250 mg
Description: 2 caplets of Ibuprofen 125 mg
Study NCT02912650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg
Description: 2 tablets of Acetaminophen 325 mg
Study NCT02912650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 caplets of Placebo
Study NCT00482651 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multidetector computed tomography scanning
Description: contrast Multidetector CT-scanning
Study NCT00482651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography (CAG)
Description: CAG and if necessary PCI. Included patients are already assigned for CAG
Study NCT00482651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: During CAG Intravascular Ultrasound will be performed in the three coronary arteries
Study NCT00482651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)